Tag: AS269
FDA Grants Fast Track Designation for ARX517 in Metastatic Castration-Resistant Prostate...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARX517, a proprietary anti-PSMA antibody-drug conjugate (ADC) investigational being therapy developed by Ambrx for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.
ARX788 First-In-Human Phase I Clinical trial in HER2 cancer patients
A First-In-Human phase I clinical trial with ARX788, an site-specific antibody-drug conjugate being developed by Ambrx® and Zhejiang Medicine has been initiated as a multicenter...
